Nephrology
KDOQI US commentary on the 2021 KDIGO Guideline for the management of blood pressure in chronic kidney disease.
24 Jan, 2022 | 07:56h | UTCRelated:
Commentary on Twitter
The @nkf KDOQI work group agreed with most of the @goKDIGO BP recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD ca. 2022 #Nephpearls
👉🏼 https://t.co/X40N0pacY6 https://t.co/HEHlSD06yO pic.twitter.com/Rpil8m0QOn
— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) January 21, 2022
RCT: In critically ill adults, using a balanced multielectrolyte solution did not lower the risk of death or acute kidney injury compared to standard saline.
19 Jan, 2022 | 08:41h | UTCBalanced Multielectrolyte Solution versus Saline in Critically Ill Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Related:
Commentary on Twitter
Trial of critically ill patients compared balanced multielectrolyte solution (BMES) with saline as fluid therapy in the ICU. There was no evidence that the risk of death or acute kidney injury was lower with the use of BMES than with saline. https://t.co/bmlg4BYaw8 pic.twitter.com/OlKGOM0Dmm
— NEJM (@NEJM) January 18, 2022
Systematic Review: Exercise training for adults undergoing maintenance dialysis.
19 Jan, 2022 | 08:32h | UTCExercise training for adults undergoing maintenance dialysis – Cochrane Library
Summary: Exercise training for adults receiving dialysis treatments – Cochrane Library
Commentary on Twitter
New Review Update: Exercise training for adults undergoing maintenance dialysis. discover the latest #CochraneEvidence https://t.co/DmtG0dA6lQ #kidney failure #exercise pic.twitter.com/STYIMpPwAN
— Cochrane Kidney + Tx (@CochraneKidney) January 13, 2022
Multi-Disciplinary Guideline: Management of nephrolithiasis in pregnancy.
16 Jan, 2022 | 23:17h | UTC
Commentary from the author on Twitter
https://t.co/bFtOYFgBmr Started as an assigned resident presentation. Turned into a set of multi-d guidelines implemented at the university level. Now published for all to reference! Thank you all authors for input & guidance @peepeeDoctor @willrobe1 @amy_krambeck @sapanambani
— Matthew Lee (@MSLee_MD) December 23, 2021
Review: New aspects in the management of hypertension in patients with chronic kidney disease not on renal replacement therapy.
11 Jan, 2022 | 02:22h | UTC
Perspective: Introducing nephrocardiology.
16 Dec, 2021 | 08:31h | UTCIntroducing Nephrocardiology – Clinical Journal of the American Society of Nephrology
Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis.
10 Dec, 2021 | 09:58h | UTC
Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors.
8 Dec, 2021 | 09:58h | UTC
Guideline: Management of ureteral calculi.
2 Dec, 2021 | 09:54h | UTCRelated Guidelines:
Cohort Study: Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease.
2 Dec, 2021 | 09:47h | UTC
Commentary from the author on Twitter (thread – click for more)
Why did observational studies find ⬆️survival for late dialysis initiation, whereas the IDEAL RCT found no difference? Was it confounding, the usual culprit we point to? No!
Our new paper @bmj_latest addresses this and much more! #epitwitter #nephtwitter https://t.co/rILigIojR1 pic.twitter.com/zDxpQMqnfE
— Edouard L. Fu (@FuEdouard) December 1, 2021
Podcast: Metabolic Alkalosis and Hypokalemia.
30 Nov, 2021 | 09:57h | UTC#308 Metabolic Alkalosis and Hypokalemia: Kidney Boy Returns! – The Curbsiders
Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.
24 Nov, 2021 | 08:33h | UTCOriginal Review: Renal denervation for resistant hypertension – Cochrane Library
Commentary on Twitter
Does renal #denervation improve outcomes in people with resistant #hypertension?❤️
Our newly updated @CochraneLibrary #SystematicReview looks at the evidence of 15 RCTs involving 1416 participants: https://t.co/NkVMHW46s6#CochraneEvidence #blogshot pic.twitter.com/TBqli3e9ai
— Cochrane Hypertension (@CochraneHTN) November 23, 2021
In a survey of about 27,600 U.S. individuals, 18.5% of adults with hypertension used medications that may raise blood pressure; the most commonly reported classes were antidepressants, nonsteroidal anti-inflammatory drugs, steroids, and estrogens.
23 Nov, 2021 | 08:33h | UTCPrevalence of Medications That May Raise Blood Pressure Among Adults With Hypertension in the United States – JAMA Internal Medicine (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
🚨New work from our team in @JAMAInternalMed 🚨
18% of adults with #hypertension report using medications (💊) that may raise blood pressure.
Use of these 💊 associated with:
⬇️ odds of achieving BP control
⬆️ # of antihypertensives usedhttps://t.co/DlV5rlHLu3Thread
/1 pic.twitter.com/q7b7FQ4jHH— Tim Anderson (@TimAndersonMD) November 22, 2021
What Is the best maintenance therapy for ANCA vasculitis?
18 Nov, 2021 | 08:34h | UTC
Systematic Review: Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
16 Nov, 2021 | 08:25h | UTCSummary: Immunosuppressive treatment for adults with idiopathic membranous nephropathy – Cochrane Library
Original Study: Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome – Cochrane Library
White-Coat Hypertension: Pathophysiological and Clinical Aspects.
12 Nov, 2021 | 09:48h | UTCWhite-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020 – Hypertension (free for a limited period)
Review: Uremic Encephalopathy.
10 Nov, 2021 | 06:49h | UTCUremic Encephalopathy – Kidney International
RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:18h | UTCDaprodustat for the Treatment of Anemia in Patients Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing maintenance hemodialysis or peritoneal dialysis. #KidneyWk https://t.co/ykzSsUlJci pic.twitter.com/0zdlMyOlTf
— NEJM (@NEJM) November 5, 2021
RCT: In patients with advanced chronic kidney disease and poorly controlled hypertension, Chlortalidone had a significant impact in blood-pressure control (−11.0 mm Hg vs. −0.5 mm Hg in the placebo group).
7 Nov, 2021 | 20:20h | UTCChlorthalidone for Hypertension in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cheap Diuretic, Chlorthalidone, Drops BP in Advanced Kidney Disease – Medscape (free registration required)
Commentary on Twitter
In this placebo-controlled trial involving patients with advanced chronic kidney disease and poorly controlled hypertension, chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with placebo. #KidneyWk https://t.co/iNZc2mYy2c pic.twitter.com/7svX4RVtPI
— NEJM (@NEJM) November 5, 2021
RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:17h | UTCDaprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial, daprodustat was as effective as darbepoetin alfa in increasing and maintaining hemoglobin levels in patients with CKD and anemia who were not receiving dialysis. #KidneyWk https://t.co/D2unQFLH6T pic.twitter.com/KqdLfVlkuD
— NEJM (@NEJM) November 5, 2021
NICE draft guideline recommends SGLT2 inhibitor dapagliflozin for some patients with chronic kidney disease.
7 Nov, 2021 | 20:14h | UTCSee draft guideline:
Appraisal consultation document (online commenting)
Appraisal consultation document (PDF version)
Related:
NICE Guideline: Assessment and management of chronic kidney disease.
Randomized trial: Dapagliflozin in patients with chronic kidney disease
M-A: Renal denervation for hypertension is associated with a modest reduction in ambulatory blood pressure control (3.61 mm Hg reduction in ambulatory systolic BP and 1.85 mm Hg reduction in ambulatory diastolic BP).
5 Nov, 2021 | 09:46h | UTCCommentaries:
Meta-Analysis of Renal Denervation for Hypertension – American College of Cardiology
Is Renal Denervation a Useful Strategy in BP Management? – American College of Cardiology
Related:
Increased temperatures contributed to more than 200,000 cases of kidney disease in 15 years in Brazil alone.
2 Nov, 2021 | 02:46h | UTC
Recurrent Glomerular Disease after Kidney Transplantation: Diagnostic and Management Dilemmas.
28 Oct, 2021 | 09:43h | UTC
Commentary on Twitter
Recurrent glomerular disease after kidney transplant remains an important cause of allograft failure. This Review focuses on clinical dilemmas encountered by physicians in managing recurrent glomerular disease https://t.co/QGZOjH7qyP
— CJASN (@CJASN) October 27, 2021
In a major scientific advance, a pig kidney is successfully transplanted into a human.
21 Oct, 2021 | 09:52h | UTCIn a major scientific advance, a pig kidney is successfully transplanted into a human – NPR